ADC Therapeutics SA (ADCT) Tops Q2 EPS by 14c

ADC Therapeutics SA (NYSE: ADCT) reported Q2 EPS of ($0.25), $0.14 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $18.84 million versus the consensus estimate of $18.05 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Array Technologies holds investor showcase on balance-of-system strategy
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance